In current clinical practice, the treatment of breast cancer is based not only on the T and N stages of patients but also on the status of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor-2 (HER-2). This evidence concerns the gene ESR1 and breast carcinoma.